Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. reduced its stake in Edwards Lifesciences Co. (NYSE:EWGet Rating) by 1.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 219,123 shares of the medical research company’s stock after selling 3,639 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Edwards Lifesciences were worth $25,795,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Mutual of America Capital Management LLC grew its stake in shares of Edwards Lifesciences by 1.1% during the first quarter. Mutual of America Capital Management LLC now owns 83,470 shares of the medical research company’s stock valued at $9,826,000 after acquiring an additional 879 shares in the last quarter. GW&K Investment Management LLC acquired a new stake in shares of Edwards Lifesciences during the first quarter valued at about $127,000. Regentatlantic Capital LLC grew its stake in shares of Edwards Lifesciences by 15.6% during the first quarter. Regentatlantic Capital LLC now owns 13,436 shares of the medical research company’s stock valued at $1,582,000 after acquiring an additional 1,813 shares in the last quarter. LPL Financial LLC grew its stake in shares of Edwards Lifesciences by 8.3% during the fourth quarter. LPL Financial LLC now owns 285,359 shares of the medical research company’s stock valued at $36,968,000 after acquiring an additional 21,931 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of Edwards Lifesciences by 12.2% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 50,075 shares of the medical research company’s stock worth $5,894,000 after purchasing an additional 5,441 shares during the last quarter. 81.33% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,725 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $90.94, for a total value of $611,571.50. Following the transaction, the vice president now owns 62,561 shares in the company, valued at $5,689,297.34. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, VP Larry L. Wood sold 7,242 shares of the firm’s stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $95.90, for a total value of $694,507.80. Following the completion of the transaction, the vice president now owns 202,232 shares of the company’s stock, valued at approximately $19,394,048.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,725 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $90.94, for a total transaction of $611,571.50. Following the completion of the transaction, the vice president now directly owns 62,561 shares of the company’s stock, valued at approximately $5,689,297.34. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,253 shares of company stock worth $6,550,960. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

NYSE EW opened at $93.35 on Friday. Edwards Lifesciences Co. has a 12 month low of $85.58 and a 12 month high of $131.73. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.37 and a quick ratio of 2.60. The firm has a market capitalization of $57.87 billion, a PE ratio of 40.41, a P/E/G ratio of 2.78 and a beta of 1.14. The company’s 50 day simple moving average is $98.30 and its 200 day simple moving average is $102.63.

Edwards Lifesciences (NYSE:EWGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The medical research company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.01). Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the prior year, the business earned $0.64 EPS. Edwards Lifesciences’s revenue was down .2% compared to the same quarter last year. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on EW. StockNews.com raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 17th. Canaccord Genuity Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $115.00 to $106.00 in a research report on Friday, July 29th. Morgan Stanley reduced their price target on shares of Edwards Lifesciences from $136.00 to $119.00 and set an “overweight” rating on the stock in a research report on Friday, July 15th. Cowen reduced their price target on shares of Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. Finally, Truist Financial reduced their price target on shares of Edwards Lifesciences from $140.00 to $120.00 and set a “buy” rating on the stock in a research report on Wednesday, July 20th. Three equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $126.19.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Recommended Stories

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.